23.35
Celldex Therapeutics Inc stock is traded at $23.35, with a volume of 969.95K.
It is up +0.56% in the last 24 hours and up +8.81% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$23.22
Open:
$23.17
24h Volume:
969.95K
Relative Volume:
1.00
Market Cap:
$1.55B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-9.0504
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
+4.19%
1M Performance:
+8.81%
6M Performance:
-2.79%
1Y Performance:
-46.76%
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CLDX
Celldex Therapeutics Inc
|
23.35 | 1.54B | 9.98M | -154.08M | -159.66M | -2.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-28-25 | Initiated | Canaccord Genuity | Buy |
Mar-20-25 | Initiated | Morgan Stanley | Overweight |
Feb-13-25 | Initiated | UBS | Buy |
Oct-07-24 | Initiated | Citigroup | Buy |
Sep-30-24 | Initiated | Goldman | Neutral |
Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jun-18-24 | Initiated | Stifel | Buy |
Jun-11-24 | Initiated | Wolfe Research | Outperform |
Dec-20-23 | Initiated | TD Cowen | Outperform |
Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Aug-22-23 | Initiated | Wells Fargo | Underweight |
Sep-17-21 | Initiated | Jefferies | Buy |
Sep-10-21 | Initiated | SVB Leerink | Outperform |
Jul-22-21 | Initiated | Guggenheim | Buy |
Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
Aug-01-17 | Resumed | H.C. Wainwright | Buy |
Nov-07-16 | Initiated | Aegis Capital | Buy |
Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
Mar-01-16 | Initiated | H.C. Wainwright | Buy |
Aug-11-15 | Reiterated | Brean Capital | Buy |
Aug-11-15 | Reiterated | Oppenheimer | Outperform |
Aug-11-15 | Reiterated | ROTH Capital | Buy |
Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
Nov-17-14 | Reiterated | ROTH Capital | Buy |
Mar-04-14 | Reiterated | Oppenheimer | Outperform |
Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
Feb-26-13 | Reiterated | Oppenheimer | Outperform |
Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
Oct-02-12 | Reiterated | Oppenheimer | Outperform |
Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Celldex Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - PrintWeekIndia
What drives Celldex Therapeutics Inc. stock priceFree Investment Risk Control - PrintWeekIndia
Why Celldex Therapeutics Inc. stock attracts strong analyst attentionFree Trading Group - Newser
What analysts say about Celldex Therapeutics Inc. stockConsistently superior profits - Autocar Professional
Is Celldex Therapeutics Inc. a good long term investmentRapidly expanding wealth - jammulinksnews.com
Is Celldex Therapeutics Inc. stock a good hedge against inflationFree Short-Term Stock Picks - Newser
What makes Celldex Therapeutics Inc. stock price move sharplySafety First Trading Signals - Newser
How Celldex Therapeutics Inc. stock performs during market volatility2x Return Forecast - beatles.ru
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, - openPR.com
Cholera Vaccines Market Deep Research and Growth in Future Scope - openPR.com
Is Celldex Therapeutics, Inc. technically bullish or bearish? - MarketsMojo
(06/24/25) CLDX: A Promising Biotech Name Targeting CSU - moneyshow.com
Chronic spontaneous urticaria improvements persist 28 weeks after barzolvolimab stopped - Healio
Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada
Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com
Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):